Report of the Advanced Prostate Cancer Consensus Conference 2022

[Graham49]

This report gives the answers to questions put to 117 “international prostate cancer experts” at the conference.

Here is an example question and summary of answers:

Q71. For patients with rising PSA and a local relapse detected by MRI and/or PSMA PET after RP who had no prior history of local sRT, 68% of panellists voted for treatment with RT (EBRT with or without boost to the lesion or SBRT) plus systemic therapy, 29% voted for RT of the prostatic bed with or without boost to the lesion, and 3% voted for SBRT of the lesion alone. There were six abstentions. (No consensus for any given answer option, no one voted for systemic therapy alone.)

doi.org/10.1016/j.eururo.20...

Background

Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management.

Objective

To present consensus voting results for select questions from APCCC 2022.

[Researcher50]

Thanks for sharing this. Clearly shows that even the experts in PCa cannot always agree on how, when and why to treat. No wonder the average patient becomes overwhelmed. I did notice that there was far more discussion about treatment plans after initial RP than initial RT. Seemed to be good consensus, though, about using PSMA-PET after either following rising PSA/BCF.

[maley2711]

Thanks .....very interesting and informative for some major questions!!!!

[j-o-h-n]

Question 56: What's for lunch?

Good Luck, Good Health and Good Humor.

j-o-h-n Thursday 07/20/2023 2:27` PM DST